Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy

BACKGROUND: Gastric cancer (GC) is a multifactorial disease with high mortality. Anti-HER2 therapy is a promising strategy in GC treatment and trastuzumab was approved by FDA (Food and Drug Administration) as the first and the second line of treatment of the disease. PURPOSE: The aim of the study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gornowicz, Agnieszka, Szymanowski, Wojciech, Czarnomysy, Robert, Bielawski, Krzysztof, Bielawska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389407/
https://www.ncbi.nlm.nih.gov/pubmed/34437575
http://dx.doi.org/10.1371/journal.pone.0255585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389407/
https://www.ncbi.nlm.nih.gov/pubmed/34437575
http://dx.doi.org/10.1371/journal.pone.0255585

Ejemplares similares